REFERENCES
1
Hull JE, et al. Computational fluid dynamic evaluation of the side-to-side anastomosis for arteriovenous fistula. J Vasc Surg. 2013;58(1):187-193
2
Results from preclinical study where 4 sheep received percutaneously created fistulae utilizing WavelinQ™ EndoAVF and the tissue healing response was evaluated at 30 ± 2 days. Data on file. GLP Animal Study, using WavelinQ™ 6F EndoAVF System. Preclinical data may not be predictive of actual clinical outcomes. Different tests methods may yield different results.
3
Yang S, et al. Comparison of post-creation procedures and costs between surgical and an endovascular approach to arteriovenous fistula creation. JVA 2017;18:8-4
4
Xi W, et al. Nephrol Dial Transplant 2011; 26:3302-3308 (Canada population).
5
2017 USRDS annual data report.
6
Cheung et al. J Am Soc Nephrol. 2017 Oct;28(10):3005-3013. Prospective, non-randomized study involving 602 patients
7
Roy-Chaudhury P, et al. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am soc Nephrol. 2006;17:1112-1127.
8
Bharat A, et al. A novel technique of vascular anastomosis to prevent juxta-anastomotic stenosis following arteriovenous fistula creation. J Vasc Surg. 2012;55(1):274-280.
9
The WavelinQ™ EndoAVF System is indicated for the creation of an arteriovenous fistula (AVF) using concomitant ulnar artery and ulnar vein or concomitant radial artery and radial vein in patients with minimum artery and vein diameters of 2.0 mm at the fistula creation site who have chronic kidney disease and need hemodialysis.